Abstract: 【Objective】The study was conducted to supply technology basis for the development of anticancer food for liver tumors from oligopeptide that derived from Auxis thazard protein developing . 【Method】 The oligopeptide was prepared from A. thazard protein by using compound enzyme hydrolysis, membrane separation and spray drying, and its molecular weight distribution, amino acid composition and mineral composition were determined. Its inhibition activities on 3 kinds of human liver cancer cells (HepG2, BEL-7402 and SMMC-7721) in vitro were determined by cell culture experiments. 【Result】 Chemical components analysis results showed that the protein content of oligopeptide derived from A. thazard was 88.9%, the total oligopeptide content was 71.96 g/100 g and its molecular weight was mainly below 1 000 u, accounting for 89.79% of the total peptide weight. Glutamic acid, lysine, aspartic acid, leucine and arginine were rich in the amino acid content, accounting for 52.41% of the total amino acids. It was rich in selenium and zinc, which was 2.84 mg/100g and 10.10 mg/100g, respectively. Cell culture results showed that, compared with the negative control group, all the oligopeptide groups showed inhibition activity on HepG2, BEL-7402 and SMMC-7721 cancer cells and had dose-effect dependence, but they did not effectively increase cisplatin inhibition activity on HepG2, BEL-7402 and SMMC-7721 cells. High dose group showed extremely significant inhibition activities on HepG2, BEL-7402 and SMMC-7721 cells, and middle dose group also had significant inhibition effect on HepG2, BEL-7402 and SMMC-7721 cells. 【Conclusion】 The oligopeptide derived from A. thazard was a good anticancer food base for liver tumors.